Datwyler was able to maintain revenue in 2023 despite the loss of the Covid business and destocking by customers. The strong project pipeline provides the basis for scaling the business model.
Datwyler increased revenue in the first half of 2023 despite negative external one-time effects.
Datwyler increased sales in 2022 thanks to leading market positions. Acquisitions and progress in growth and innovation projects have further strengthened the strategic position.
Datwyler delivered a solid performance in the first half of 2022 in a difficult environment thanks to strong market positions.
14th sustainability report in accordance with GRI guidelines.
Learn more about how the pharma industry is taking charge to improve environmental, social, and governance (ESG) critical issues.
Datwyler is now focusing exclusively on system-critical elastomer components. The continuing operations generated record revenue and currency-adjusted growth of 15.0%.
With twelve focus topics, the company aims to reduce its environmental footprint and create added value for all stakeholders.
Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.
